About billiontoone inc - BLLN
BillionToOne, Inc. is a next-generation molecular diagnostics company on a mission to create powerful and accurate tests that are accessible to all. The company’s patented Quantitative Counting Templates (QCT) molecular counting platform is a multiplex technology capable of accurately counting DNA molecules at the single-molecule level. BillionToOne was founded by Oguzhan Atay, Sukrit Silas, and David Tsao in 2016 and is headquartered in Menlo Park, CA.
BLLN At a Glance
BillionToOne, Inc.
1035 O'Brien Drive
Menlo Park, California 94025
| Phone | 1-650-460-2551 | Revenue | 305.11M | |
| Industry | Medical/Nursing Services | Net Income | 2.92M | |
| Sector | Health Services | 2025 Sales Growth | 99.966% | |
| Fiscal Year-end | 12 / 2026 | Employees | 713 | |
| View SEC Filings |
BLLN Valuation
| P/E Current | 1,245.84 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 1,284.772 |
| Price to Sales Ratio | 12.286 |
| Price to Book Ratio | 7.808 |
| Price to Cash Flow Ratio | 152.42 |
| Enterprise Value to EBITDA | 120.357 |
| Enterprise Value to Sales | 11.018 |
| Total Debt to Enterprise Value | 0.032 |
BLLN Efficiency
| Revenue/Employee | 427,927.069 |
| Income Per Employee | 4,093.969 |
| Receivables Turnover | 7.331 |
| Total Asset Turnover | 0.653 |
BLLN Liquidity
| Current Ratio | 11.688 |
| Quick Ratio | 11.322 |
| Cash Ratio | 10.341 |
BLLN Profitability
| Gross Margin | 68.322 |
| Operating Margin | 5.252 |
| Pretax Margin | 2.543 |
| Net Margin | 0.957 |
| Return on Assets | 0.625 |
| Return on Equity | 0.901 |
| Return on Total Capital | 0.496 |
| Return on Invested Capital | 0.683 |
BLLN Capital Structure
| Total Debt to Total Equity | 22.681 |
| Total Debt to Total Capital | 18.488 |
| Total Debt to Total Assets | 17.212 |
| Long-Term Debt to Equity | 21.516 |
| Long-Term Debt to Total Capital | 17.538 |